patent.fyi
Applications  /  US 2026/0355160
United States Patent Application Publication

US 2026/0355160 A1

Published
Nov 12, 2026
Filed
Jul 13, 2026
Earliest date on the face
Jul 23, 2021
Classification
A61K 31/407
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Corticosteroid for inflammation control

What ifWhat if dexamethasone sodium phosphate provides the anti-inflammatory action?
Claim language“a pharmaceutically acceptable salt of ketorolac”

Dexamethasone sodium phosphate dissolves in a sterile aqueous carrier. Ocular phosphatases release dexamethasone, which activates glucocorticoid receptors and reduces inflammatory signaling.

1.1Epinephrine for pupil dilation

What ifWhat if epinephrine provides pupil dilation during surgery?
Claim language“a pharmaceutically acceptable salt of phenylephrine”

A sterile epinephrine solution is diluted into an intraocular irrigation fluid before the procedure. Epinephrine stimulates alpha-adrenergic receptors in the iris dilator muscle and promotes contraction of that muscle.

1.2Citrate-buffered aqueous carrier

What ifWhat if a citrate buffer controls the pH of the aqueous composition?
Claim language“lacks a buffer”

Citric acid and sodium citrate establish an acidic pH during compounding. The citrate species take up or release protons as the acid load changes, reducing pH drift in the sealed vial.

1.2Edetate binds trace metals

What ifWhat if dissolved disodium edetate binds trace metals in the aqueous composition?
Claim language“lacks a chelator”

Disodium edetate complexes dissolved iron and copper ions. Complexation reduces the amount of free metal available to catalyze oxidation.

1.2Refrigerated storage and testing

What ifWhat if the finished vials use a refrigerated storage program at 2–8 °C?
Claim language“a temperature of about 40 °C”

The lower temperature slows temperature-dependent degradation during storage. Liquid chromatography measures both active ingredients and degradation products at filling and after one month to assess stability under refrigeration.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Perfusion of isolated porcine eyes

An ex vivo ocular test bench uses a buffer-free, chelator-free aqueous concentrate of ketorolac tromethamine and phenylephrine hydrochloride. A metering syringe introduces the concentrate into a carrier stream upstream of a cannula that perfuses the anterior chamber of an isolated porcine eye. A camera records pupil diameter, and an inline pressure transducer records perfusion pressure during exposure.

Component substitution

Ketorolac sodium in the concentrate

Ketorolac sodium replaces ketorolac tromethamine as the ketorolac source. The sodium salt and phenylephrine hydrochloride dissolve in water for injection, and the sodium salt mass is calculated from the target molar concentration of ketorolac. The formulation contains neither a buffer nor a chelator. Chromatographic assays measure each active and the total impurities at filling and after storage.

Parameter or scale variation

Two fill volumes with matched headspace

The same buffer-free, chelator-free aqueous blend fills glass vials at nominal liquid volumes of 1 mL and 5 mL. Vial and stopper geometry set the corresponding sealed headspace volumes to 0.25 mL and 1.25 mL, giving both sizes a headspace-to-liquid ratio of 0.25. Replicate vials from each size enter the same storage chamber, and assays compare active retention and total impurities at matched sampling times.

Repeated cold and warm storage cycles

Sealed vials of the buffer-free, chelator-free aqueous formulation undergo 15 cycles of 24 hours at 5 °C followed by 24 hours at 30 °C. Separate vials from the same fill lot remain at 25 °C for the 30-day comparison. Dedicated vials are opened at baseline and after cycles 5, 10, and 15 for pH, active content, and total impurity measurements.

Combination with existing systems

Metered addition to ophthalmic irrigation

A syringe pump holds the aqueous ketorolac and phenylephrine concentrate in a separate sterile fluid path. A check valve and a Y-connector join the concentrate path to the outlet line of an ophthalmic irrigation reservoir, and a static mixer sits downstream of the junction. The syringe pump meters concentrate in proportion to carrier flow and pauses dosing when carrier flow stops.

Automated or data-driven variant

Automated tracking of storage stability

Barcoded vials of the aqueous formulation occupy assigned positions in temperature and humidity chambers. Scheduling software generates chromatographic sample sequences from vial identifiers, chamber assignments, and sampling dates. Analysis software calculates retention for each active from its time-zero assay and calculates total impurities from the integrated impurity peaks using stored response factors. The software flags retention below 98% for either active and total impurities at or above 0.5%.

Specific version of a part

Tromethamine and hydrochloride salts

Ketorolac tromethamine supplies ketorolac, and phenylephrine hydrochloride supplies phenylephrine. Both salts dissolve in water for injection to form an aqueous solution.

Direct ph adjustment

Dilute hydrochloric acid or sodium hydroxide adjusts the bulk solution to the target pH during compounding. The formulation contains no added buffer or chelator.

One-month chromatographic stability check

Sealed vials are stored for one month at 25 ± 2 °C and about 60% relative humidity. Liquid chromatography compares both active ingredients with their initial amounts and measures total impurities against the limits of at least 98% retention for either active or both and less than 0.5% total impurities.

Cite aspatent.fyi, US 2026/0355160 A1, claim 1, first published 2026-11-19T08:28:42-05:00, https://patent.fyi/US20260355160/, SHA-256 ca63a59dd3a6b4d91361cae30246caf336837409536e6ad42194d775c2b191f2
First published
Permanent addresshttps://patent.fyi/US20260355160/
Content fingerprint (SHA-256)ca63a59dd3a6b4d91361cae30246caf336837409536e6ad42194d775c2b191f2
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi